Prolong Pharmaceuticals
Prolong Pharmaceuticals is a privately held, clinical-stage biopharmaceutical company developing PEGylated carboxyhemoglobin bovine (PP-007/Sanguinate®) using its proprietary PEGfinity™ platform to treat ischemia and hypoxia in acute ischemic stroke, sickle cell disease, cystic fibrosis, and hemorrhagic shock.
- Company typePrivate
- Founded2005
- HeadquartersSouth Plainfield, United States
- Headcount51–100
- GTM typeB2B
- OfferingHardware or Manufacturing
What Prolong Pharmaceuticals does
Prolong Pharmaceuticals is a privately held, clinical-stage biopharmaceutical company founded in 2005 and headquartered in South Plainfield, New Jersey, that develops PEGylated protein therapeutics for ischemia and hypoxia-related conditions. The company's core product is PP-007 (Sanguinate®), a PEGylated carboxyhemoglobin bovine (PCHB) nano-sized oxygen carrier designed as an acellular, dual-action carbon monoxide-releasing and oxygen-transfer agent that selectively oxygenates hypoxic tissue and reduces inflammation. The lead clinical indication is acute ischemic stroke (AIS), with the HEMERA-1 Phase 1/2 trial supporting that program; additional pipeline indications include sickle cell disease vaso-occlusive crisis, cystic fibrosis-related lung inflammation, and hemorrhagic shock/trauma resuscitation.
The company develops its candidates through its proprietary PEGfinity™ platform, which integrates PEGylation chemistry with in-silico analytical methods for protein modification, lead optimization, and structure-function analysis. PEGylation is a well-established drug-delivery modality used in FDA-approved therapies such as Neulasta® and Krystexxa®, and Prolong's founders contributed to the first FDA approval of a PEGylated protein therapeutic (Adagen®, 1990). The company has received FDA Breakthrough Therapy Designation and Fast Track Designation for PP-007 in AIS, and holds patent application WO2024081928 covering a stable hemoglobin protein mixture composition.
Prolong currently generates no commercial revenue: the company operates as a clinical-stage developer, distributing its investigational drug directly to clinical trial sites, and its Expanded Access Policy states it does not provide PP-007 outside of active clinical trials. Upon potential regulatory approval, commercial distribution would flow through hospital pharmacies, specialty pharmacies, and acute-care providers, particularly in stroke treatment settings. The company is backed by two single-family office investors, Avtar Investments and Tarsadia, and is led by CEO Dr. Sandeep Athalye alongside a management team with prior experience at Biocon Biologics, Boehringer Ingelheim, Novartis, Roche, Mylan, Pfizer, and Sandoz.
Prolong Pharmaceuticals firmographics
Firmographics- Name
- Prolong Pharmaceuticals
- Legal name
- Prolong Pharmaceuticals, LLC
- Website
- https://prolongpharma.com
- Company type
- Private
- Founded year
- 2005
- Operating status
- Operating
- Headcount range
- 51–100 employees
- Short description
- Prolong Pharmaceuticals is a privately held, clinical-stage biopharmaceutical company developing PEGylated carboxyhemoglobin bovine (PP-007/Sanguinate®) using its proprietary PEGfinity™ platform to treat ischemia and hypoxia in acute ischemic stroke, sickle cell disease, cystic fibrosis, and hemorrhagic shock.
- Ownership category
- akta.pro rank
Prolong Pharmaceuticals industry classification
Industry- Product category
- Biopharmaceutical Therapeutics (Oxygen Delivery / Anti-Ischemia)
- NAICS
- Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical Preparation Manufacturing (325412)
- SIC
- Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836)
- akta.pro primary industry
- Cardiology & Vascular Specialty Pharmaceuticals (HLAIACAG)
- akta.pro secondary industry
- Lead Optimization & Preclinical Candidate Selection (HLAIALAB)
Keywords
Where Prolong Pharmaceuticals is headquartered
LocationHeadquarters
- HQ city
- South Plainfield
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
Prolong Pharmaceuticals business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations, Supply Chain, Marketing or Sales, Infrastructure
Distribution channels1 record
Marketing channels4 records
Prolong Pharmaceuticals product offering
Product offeringCore offering
Prolong Pharmaceuticals is developing PP-007 (Sanguinate®), a PEGylated carboxyhemoglobin bovine (PCHB) oxygen carrier built on its proprietary PEGfinity™ platform. PP-007 is an acellular, dual-action carbon monoxide releasing molecule and oxygen transfer agent designed to selectively oxygenate hypoxic tissue, improve perfusion, and reduce inflammation in conditions of ischemia and hypoxia. Lead indications include acute ischemic stroke, sickle cell disease vaso-occlusive crisis, cystic fibrosis, and hemorrhagic shock/trauma.
Product overview
Prolong Pharmaceuticals is a clinical-stage biopharmaceutical company with a single core product focus. Their lead biopharmaceutical candidate is PP-007, branded as Sanguinate®, which is developed using the proprietary PEGfinity™ platform technology. PP-007 is a PEGylated carboxyhemoglobin bovine (PCHB) product designed as an oxygen carrier and carbon monoxide releasing molecule for treating conditions of ischemia and hypoxia, with primary development targeting acute ischemic stroke. The PEGfinity™ platform enables the company's PEGylation-based drug development approach for protein therapeutics.
Differentiator
Problem solved
Functional benefit
Brands
- Sanguinate®: PEGylated carboxyhemoglobin bovine (PCHB) product for treating acute ischemic stroke and other conditions of ischemia/hypoxia.
- PEGfinity™
Products and services
- PP-007 (Sanguinate®) PP-007 (Sanguinate®) is a PEGylated carboxyhemoglobin bovine (PCHB) nano-sized oxygen carrier functioning as an acellular, dual-action carbon monoxide releasing molecule and oxygen transfer agent. It selectively oxygenates hypoxic tissues, improves perfusion, and reduces inflammation, addressing ischemia and hypoxia in acute ischemic stroke, sickle cell disease vaso-occlusive crisis, cystic fibrosis, and hemorrhagic shock/trauma. It is developed for hospital and acute care use and is currently an investigational drug under clinical development.
Quantifiable outcome
- NIHSS scores at 24 hours: 8.63 for PP-007+MT vs 16.25 for MT only (p<0.05) - statistically significant improvement
- +3 more outcomes
Companies that use Prolong Pharmaceuticals
Customer profileSegments4 records
Ideal customer profiles4 records
Prolong Pharmaceuticals technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature3 records
Prolong Pharmaceuticals partnerships and signals
Strategic signalScale indicators2 records
Recent moves6 records
Expansion highlights5 records
Prolong Pharmaceuticals competitors and assessment
Company assessmentDirect peers
- DiaMedica Therapeutics: Direct indication overlap in acute ischemic stroke with a clinical-stage asset (DM199), making it the most relevant pure-play comparable for AIS commercial modeling.
- HbO2 Therapeutics: Closest direct peer: also developing a PEGylated hemoglobin-based oxygen carrier (Hemopure-class / Hemoglobin-based Oxygen Carrier) for trauma, ischemia, and sickle cell indications. Competes with Prolong on the same HBOC modality and overlapping indications.
- Kashiv Biosciences: Closely affiliated clinical-stage biologics developer led by overlapping management (CEO Dr. Athalye, SVP Pakulski, Head of Ops Dr. Rawal, Director Pandya) with biosimilars and PEGylated biologic programs; provides a structural and operational comparable for Prolong's CMC and regulatory execution.
Emerging players
- Athersys (now Healios): Developed MultiStem cell therapy for ischemic stroke and ARDS, a directly comparable regenerative/adjunctive approach for acute ischemic stroke at similar clinical stage.
- Acticor Biotech: Clinical-stage stroke biotech developing glenzocimab (anti-GPVI antibody) for acute ischemic stroke, targeting the same thrombectomy-adjunctive use case as PP-007.
- Tenax Therapeutics: Develops levosimendan for cardiovascular indications including cardiogenic shock and PH-HFpEF; comparable oxygen-delivery/hemodynamic-support mechanism and similar clinical-stage profile.
- DiaMedica Therapeutics: Clinical-stage biopharma developing DM199 (rhKLK1) for acute ischemic stroke, directly overlapping Prolong's lead indication. Prolong's CMO Dr. Kirsten Gruis previously served as CMO at DiaMedica, highlighting comparable stage and therapeutic focus.
Broad incumbents
- Genentech / Roche (Activase/tPA franchise): Sells the dominant AIS thrombolytic (Activase/alteplase) and is advancing tenecteplase in stroke; represents the standard-of-care incumbent whose behavior shapes PP-007's commercial uptake and clinical positioning.
- Nektar Therapeutics: Established PEGylation platform company (PEGylation chemistry underpinning multiple approved drugs), comparable to Prolong's PEGfinity platform from a technology-and-modality perspective, though focused on small-molecule and polymer conjugates.
Others
- Sanguine Biosciences: Biospecimen and clinical-research-services provider supporting biologic and cell-therapy developers; adjacent enabling vendor for clinical-stage biologics programs like PP-007.
Market position
Strengths4 records
Weaknesses5 records
Competitive moat3 records
Key risks6 records
Key highlights7 records
Customer concentration
Prolong Pharmaceuticals social profiles
Digital presenceProlong Pharmaceuticals financial estimates
Financial estimateRevenue estimate
Valuation estimate
Prolong Pharmaceuticals leadership team
Management profileNumber of profiles
Profiles5 records
Prolong Pharmaceuticals funding detail
Funding detailFunding overview
Funding rounds2 records
Investors1 record
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Prolong Pharmaceuticals M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Prolong Pharmaceuticals
What does Prolong Pharmaceuticals do?
Prolong Pharmaceuticals is developing PP-007 (Sanguinate®), a PEGylated carboxyhemoglobin bovine (PCHB) oxygen carrier built on its proprietary PEGfinity™ platform. PP-007 is an acellular, dual-action carbon monoxide releasing molecule and oxygen transfer agent designed to selectively oxygenate hypoxic tissue, improve perfusion, and reduce inflammation in conditions of ischemia and hypoxia. Lead indications include acute ischemic stroke, sickle cell disease vaso-occlusive crisis, cystic fibrosis, and hemorrhagic shock/trauma.
Is Prolong Pharmaceuticals a public or private company?
Prolong Pharmaceuticals is a private company. It is classified as venture growth investor backed and is currently operating.
When was Prolong Pharmaceuticals founded?
Prolong Pharmaceuticals was founded in 2005. It employs 51 to 100 people.
Where is Prolong Pharmaceuticals based?
Prolong Pharmaceuticals is headquartered in South Plainfield, United States, in the North America region.
Who are Prolong Pharmaceuticals's main competitors?
Direct peers on record are DiaMedica Therapeutics, HbO2 Therapeutics and Kashiv Biosciences. Emerging players are Athersys (now Healios), Acticor Biotech, Tenax Therapeutics and DiaMedica Therapeutics. Broad incumbents are Genentech / Roche (Activase/tPA franchise) and Nektar Therapeutics. Sanguine Biosciences is listed as an others.
Does Prolong Pharmaceuticals have an API?
No public API is recorded for Prolong Pharmaceuticals.
What industry is Prolong Pharmaceuticals in?
Prolong Pharmaceuticals's product category is Biopharmaceutical Therapeutics (Oxygen Delivery / Anti-Ischemia). Its primary akta.pro industry code is HLAIACAG, Cardiology & Vascular Specialty Pharmaceuticals, with a secondary code of HLAIALAB, Lead Optimization & Preclinical Candidate Selection. Its NAICS code is 325414 and its SIC code is 2834.